News

AbstractHLA-identical sibling donor hematopoietic cell transplant (HCT) is an established curative therapy for sickle cell disease (SCD). Although myeloablative HCT…

AbstractSickle cell disease (SCD) affects millions worldwide, yet the limited treatment options currently available do not always adequately control the disease and…

AbstractBackgroundExagamglogene autotemcel (exa-cel) is a cell therapy in which autologous CD34+ hematopoietic cells are engineered through ex vivo clustered…

AbstractIntroduction: Sickle cell disease (SCD) is a group of inherited blood diseases in which the affected person inherits two abnormal haemoglobin genes from…

Courtney is an Ivy League–educated investment banker on Wall Street. She loves to travel, enjoys Broadway musicals and lives in New York City with her two best…

Stem cell transplant from a partially matched donor is more cost-effective than gene therapy to treat sickle cell disease (SCD), according to a study.In order for…

A 10-year study in sub-Saharan Africa revealed that a higher dose of the oral medication Hydroxyurea improved survival and growth outcomes in children with sickle…

Dr. Maureen M. Achebe is Clinical Director of Hematology, Brigham and Women's Hospital, Boston, Massachusetts. She is an Associate Professor of Medicine and Global…

June 19, marks World Sickle Cell Day, with the 2026 theme focusing on closing the survival gap and a push towards a universal cure. 20 years have passed since the…

AbstractSickle cell disease (SCD) is a systemic vasculopathy, which progressively remodels the heart and pulmonary circulation through chronic anemia, hemolysis,…